Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription - A multilevel methodological approach

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Ohlsson, Henrik ^a,b   Merlo, Juan ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b Department of Health and Health Care Management   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGED; ARTICLE; BUDGET; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTROLLED STUDY; DECENTRALIZATION; ECONOMIC ASPECT; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PUBLIC HEALTH; REGRESSION ANALYSIS; RISK; DRUG USE; ECONOMICS; EVIDENCE BASED MEDICINE; PRIMARY HEALTH CARE; PRIVATE PRACTICE; PUBLIC HEALTH SERVICE; RESIDENTIAL CARE; STANDARD; STATISTICS; SWEDEN; TIME;

BUDGETS; CATCHMENT AREA (HEALTH); DRUG UTILIZATION REVIEW; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PRIVATE PRACTICE; PUBLIC HEALTH ADMINISTRATION; REGRESSION ANALYSIS; SWEDEN; TIME FACTORS;

EID: 34249800114     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-68     Document Type: Article

References (52)

1. Adherence to the guidelines of a regional formulary. G Kamps R Stewart G van Der Werf J Schuling BM Jong, Fam Pract 2000 17 3 254 260 10846146
2. Disseminating practice guidelines to physicians. AT Koutsavlis, Institut national de santé publique du Québec 2001
3. Factors influencing adherence to guidelines in general practice. RE Stewart S Vroegop GB Kamps GT van der Werf B Meyboom-de Jong, Int J Technol Assess Health Care 2003 19 3 546 554 12962342
4. Drug therapeutics committees: a Swedish experience. F Sjöqvist M-L Dahl L Gustafsson L-O Hensjö WHO Drug Information 2002 16 207 213
5. Lag (1996:1157) om läkemedelskommittéer. (Law (1996:1157) about drug committees) [in Swedish]. Socialdepartementet
6. Beslut (469/2003). AL Edling, 2003
7. Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study. WN Kasje P Denig RE Stewart PA de Graeff FM Haaijer-Ruskamp, Eur J Clin Pharmacol 2005 61 2 145 151 15761751
8. En uppföljning av läkemedelskommitéernas arbete. Hur påverkas läkemedelsanvändningen ? (A follow-up of the effort of the drug committees. How does it affect the drug use?) [in Swedish]., Socialstyrelsen
9. Understanding adherence to official guidelines on statin prescribing in primary health care-a multi-level methodological approach. H Ohlsson U Lindblad T Lithman B Ericsson UG Gerdtham A Melander L Rastam J Merlo, Eur J Clin Pharmacol 2005 61 9 657 665 16133551
10. Swedish Health Care in an International Context. Regions SAoLAa. Stockholm 2005
11. Decentraliserad läkemedelsbudget 2004 (Decentralized drug budget) [In Swedish]. T Lithman D Noréen, 2004
12. Evaluation of the effects of statins (with particular consideration of atorvastatin). Cologne: Institut fur Qualität und Wirtschaftlichkeit im Gesundheitswesen 2006
13. Behandling med lipidsänkande läkemedel vid prevention av hjärt-kärlsjukdomar. (Treatment with lipid-lowering drugs for prevention of heart diseases) [in Swedish]. Information från Läkemedelsverket 2003 14 ISSN 1101-7104 4
14. Bakgrundsmaterial (Backgroundmaterial) [in Swedish]. Lä kemedelsrådet (ed), Lund 2006
15. Decentralisation as an organisational model for health care in England. S Peckham M Exworthy M Powell I Greener, 2005
16. Multilevel Statistical Models. H Goldstein, London, UK: Hodder Arnold 3 2003
17. Multilevel analysis: an introduction to basic and advanced multilevel modeling. T Snijders R Bokser, Thousand Oaks, California: Sage Publications 1999
18. Lag om receptregister (1996:1156) Proposition 1996/97:27 om läkemedelsförmåner och läkemedelsförsörjning m.m (Swedish National Prescription Register Law). 1996
19. About the ATC/DDD system. http://www.whocc.no/atcddd/
20. On some points relating to vital statistics, more expecially statistics of occupational mortality. G Yule Udny, Journal of the Royal Statistical Society 1934 97 1 1 84
21. Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain. J Merlo J Ranstam L Rastam A Wessling A Melander, Eur J Clin Pharmacol 1994 46 5 393 398 7957531
22. Assessment of the magnitude of geographical variations and socioeconomic contextual effects on ischaemic heart disease mortality: a multilevel survival analysis of a large Swedish cohort. B Chaix M Rosvall J Merlo, J Epidemiol Community Health 2007 61 4 349 355 17372297
23. Skånelistan 2006 [in Swedish]. Lund, Läkemedelsrådet, 2006
24. A brief conceptual tutorial of multilevel analysis in social epidemiology : investigating contextual phenomena in different groups of individuals. J Merlo M Yang B Chaix J Lynch, J Epidemiol Community Health 2005 59 9 729 36 16100308
25. A User's Guide to MLwiN, Version 2.0. Documentation Version 2.1e. J Rasbash F Steele W Browne, London, UK: Centre for Multilevel Modelling, Institute of Education, University of London 2003
26. Rational prescribing and interpractitioner variation. A multilevel approach. P Davis B Gribben, Int J Technol Assess Health Care 1995 11 3 428 442 7591545
27. How much variation in clinical activity is there between general practitioners? A multi-level analysis of decision-making in primary care. P Davis B Gribben R Lay-Yee A Scott, J Health Serv Res Policy 2002 7 4 202 208 12425779
28. Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression. K Larsen J Merlo, Am J Epidemiol 2005 161 1 81 88 15615918
29. Interpreting parameters in the logistic regression model with random effects. K Larsen JH Petersen E Budtz-Jorgensen L Endahl, Biometrics 2000 56 3 909 914 10985236
30. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Merlo B Chaix H Ohlsson A Beckman K Johnell P Hjerpe L Rastam K Larsen, J Epidemiol Community Health 2006 60 4 290 297 16537344
31. League tables and their limitations: Statistical issues in comparisions of institutional performance. H Goldstein D Spiegelhalter, J R Statist Soc 1996 159 Part 3 385 443
32. MCMC Estrimation in MLwiN (Version 2.0). W Browne, London: Institute of Education University of London 2003
33. Evaluating and Improving Physician Prescribing. S Soumerai S Majumdar H Lipton, Pharmacoepidemiolgy Chichester, UK: Wiley, Strom B, 3 2000 483 503
34. Effectiveness and efficiency of guideline dissemination and implementation strategies. J Grimshaw R Thomas G Maclennan C Fraser C Ramsay L Vale P Whitty M Eccles L Matowe L Shirran, Health Technol Assess 2004 8 6 14960256
35. Implications of the results of community intervention trials. G Sorensen K Emmons MK Hunt D Johnston, Annu Rev Public Health 1998 19 379 416 9611625
36. Why we need observational studies to evaluate the effectiveness of health care. N Black, Bmj 1996 312 7040 1215 1218 8634569
37. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. MA Brookhart DH Solomon P Wang RJ Glynn J Avorn S Schneeweiss, J Clin Epidemiol 2006 59 1 18 25 16360557
38. Therapeutic traditions and compliance with local therapeutic guidelines on lipid lowering drugs - a multilevel analysis in the Skaraborg Primary Healthcare Database (SPHD). P Hjerpe S Fornwall J Merlo, International society for pharmacoepidemiology Bordeaux 2004
39. Wrestling with variation: an interview with Jack Wennberg [interviewed by Fitzhugh Mullan]. J Wennberg, Health Aff (Millwood) 2004 Suppl Web Exclusive VAR73 80
40. Professional uncertainty and the problem of supplier-induced demand. JE Wennberg BA Barnes M Zubkoff, Soc Sci Med 1982 16 7 811 824 7100999
41. Medical practice variations revisited. HL Smits, Health Aff (Millwood) 1986 5 3 91 96 3792991
42. Small area variations: a critical review of propositions, methods, and evidence. S Folland M Stano, Med Care Rev 1990 47 4 419 465 10170813
43. Variability in prescription drug utilization: issues for research. AH Anis SG Carruthers AO Carter J Kierulf, Cmaj 1996 154 5 635 640 8603319
44. Evaluation del uso apropiado de medicamentos en atencion primaria. Como se puede mejorar? (Evaluation of the appropriate use of medication in primary care - how do we improve it?) [in Spanish]. B Lopez-Valcarcel V Ortun-Rubio A Cabez-Mora A Lopez-Cabãas J Diaz-Berenger F Alamo-Santana, Aten Primaria 2002 30 467 471 12406416
45. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. T Walley P Folino-Gallo P Stephens E Van Ganse, Br J Clin Pharmacol 2005 60 5 543 551 16236045
46. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. M Teeling K Bennett J Feely, Br J Clin Pharmacol 2005 59 2 227 232 15676046
47. A qualitative comparative investigation of variation in general practitioners' prescribing patterns. C Jaye M Tilyard, Br J Gen Pract 2002 52 478 381 386 12014535
48. Produktresumén revideras för Crestor. Läkemedelsverket
49. Landsomfattande konsensus för behandling av höga blodfetter (För landets läkemedelskommittéordförande LOK). O Ohlsson T Kjellström, Lund, Sweden 2003
50. The statin wars : why AstraZeneca must retreat. Lancet 2003 362 9393 1341 14585629
51. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. J Merlo H Liedholm U Lindblad A Bjorck-Linne J Falt G Lindberg A Melander, Bmj 2001 323 7310 427 428 11520839
52. Prescribing, prescription costs and adherence to formulary committee recommendations: long-term differences between physicians in public and private care. A Hakansson H Andersson H Cars A Melander, Eur J Clin Pharmacol 2001 57 1 65 70 11372595